Abcl stock forecast.

Nov 27, 2023 · Get the latest information on AbCellera Biologics Inc. (ABCL), a biotechnology company that discovers antibodies from natural immune responses. See its stock price, earnings, revenue, financial statements, analyst forecasts, news and more.

Abcl stock forecast. Things To Know About Abcl stock forecast.

For Abcam plc stock forecast for 2026, 12 predictions are offered for each month of 2026 with average Abcam plc stock forecast of 1878.0, a high forecast of 2240.87, and a low forecast of 1688.28. The average Abcam plc stock forecast 2026 represents a 53.18% increase from the last price of 1226.0.AbCellera Biologics ’s ( ABCL) Moving Averages Convergence Divergence (MACD) indicator is -0.21, suggesting AbCellera Biologics is a Sell. AbCellera Biologics ’s ( ABCL) 20-Day exponential moving average is 4.29, while AbCellera Biologics ’s ( ABCL) share price is $4.43, making it a Sell. AbCellera Biologics ’s ( ABCL) 50-Day ...JYNT. The Joint Corp. 9.24. -0.01. -0.11%. In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap ...Nov 27, 2023 · Get the latest information on AbCellera Biologics Inc. (ABCL), a biotechnology company that discovers antibodies from natural immune responses. See its stock price, earnings, revenue, financial statements, analyst forecasts, news and more.

ABCL stock forecast for 2023 – 2027. Last updated: October 5, 2023. ABCL. AbCellera Biologics Inc. 4.43 D 1.14% (0.05) Are you interested in AbCellera Biologics Inc. stocks prediction? If yes, then on this page you will find useful information about the dynamics of the ABCL stock price in 2022-2027. Is ABCL a good long term stock? When should ...

Analyst Forecast. According to 41 analysts, the average rating for NVDA stock is "Strong Buy." The 12-month stock price forecast is $609.89, which is an increase of 30.42% from the latest price.Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating.

AbCellera Biologics Inc. research and ratings by Barron's. View ABCL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Nov 25, 2023 · At the close of trading, the stock’s price was $4.50, to imply an increase of 1.58% or $0.07 in intraday trading. The ABCL share’s 52-week high remains $14.15, putting it -214.44% down since that peak but still an impressive 14.0% since price per share fell to its 52-week low of $3.87. The current average ABCL price target, as estimated by these analysts, is $27.75. The predictions for the future ABCL stock price range from a low of $18.00 to a high of $34.00 , highlighting the variability of market expectations for ABCL . 2,065.00 -2.10(-0.10%) AbCellera Biologics Inc. (ABCL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 4.7800 +0.0500 (+1.06%) At close: 04:00PM EST 4.7600 -0.02 (-0.42%)...

Key points: Despite only being released into the Australian market a few months ago, Mounjaro is in short supply. It has been approved by the TGA as a …

People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.

Shares of AmerisourceBergen Corp. ABC, slumped 0.33% to $166.85 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX, -0.09% rising ...AbCellera Biologics Inc. research and ratings by Barron's. View ABCL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Nov 13, 2023 · High Growth Earnings: ABCL is forecast to remain unprofitable over the next 3 years. Revenue vs Market: ABCL's revenue (23.9% per year) is forecast to grow faster than the US market (8% per year). High Growth Revenue: ABCL's revenue (23.9% per year) is forecast to grow faster than 20% per year. Nov 24, 2023 · On a fall, the stock will find some support from the long-term average at approximately $4.30. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. A buy signal was issued from a pivot bottom point on Friday, October 27, 2023, and so far it has risen 13.30%. ABCELLERA BIOLOGICS share price in real-time (A2QKXS / CA00288U1066), charts and analyses, news, key data, turnovers, company data.The average twelve-month price prediction for AbCellera Biologics is $21.88 with a high price target of $34.00 and a low price target of $12.00. Learn more on ABCL's analyst rating history. Do Wall Street analysts like AbCellera Biologics more than its competitors?Nov 29, 2023 · See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $22.33, which predicts an increase of …Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of $10.00 to a high of $32.00 ...A high-level overview of AbCellera Biologics Inc. (ABCL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.View 8 reports from 3 analysts offering long term price targets for Aditya Birla Capital Ltd.. Aditya Birla Capital Ltd. has an average target of 205.67. The consensus estimate represents an upside of 21.05% from the last price of 169.90. Reco - This broker has downgraded this stock from it's previous report.According to analyst projections, ABCL’s forecast low is $10.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -639.13% plunge from its current level, while the stock would need to soar -117.39% for it to hit the projected low. AbCellera Biologics Inc (ABCL) estimates and forecasts

Over the past year, ABCL has underperformed the S&P 500, with a price decline of 28.37% against the S&P 500's growth of 17.07%. Data by YCharts. ABCL's market cap stands at $2.07B, with total debt ...Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.A high-level overview of AbCellera Biologics Inc. (ABCL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.AbCellera Biologics (ABCL) Stock Forecast & Price Target $4.43 0.00 (0.00%) (As of 11/24/2023 ET) Compare Today's Range $4.40 $4.49 50-Day Range $3.91 $5.13 52 …Find the latest AbCellera Biologics Inc. (ABCL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.The above table shows the analyst ABCL forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$4.83An XYZ stock analysis is the complement to an ABC analysis, and adds a layer of statistical review that shows the standard deviation of usage. ... Based on these classifications, companies can use the demand forecast and XYZ material classification to determine optimal order schedules.Find the latest Standard Lithium Ltd. (SLI) stock quote, history, news and other vital information to help you with your stock trading and investing.1 Month Ago. -$0.12. 3 Months Ago. -$0.14. AbCellera Biologics Inc. analyst estimates, including ABCL earnings per share estimates and analyst recommendations.

ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only.

The Bureau of Meteorology and AFAC summer outlook shows Australia is not off the hook for hot summer temperatures and a heightened bushfire risk, despite …

Aditya Birla Cap. share price was Rs 169.90 as on 01 Dec, 2023, 03:59 PM IST. Aditya Birla Cap. share price was up by 1.13% based on previous share price of Rs. 169.15. In last 1 Month, Aditya Birla Cap. share price moved down by 0.12%. 2.Future criteria checks 4/6. Palantir Technologies is forecast to grow earnings and revenue by 34.8% and 18% per annum respectively. EPS is expected to grow by 33.7% per annum. Return on equity is forecast to be 18.4% in 3 years.Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. We don't have any Insights for this stock currently. Aditya Birla Cap. Share Price Returns. 1 Day, 1.67%. 1 Month ...AbCellera Biologics Stock Chart and Share Price Forecast, Short-Term "ABCL" Stock Prediction for Next Days and Weeks Walletinvestor.com AbCellera Biologics Inc (ABCL) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 Based on 1 Wall Street analysts offering 12 month price targets for Orasure Technologies in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 6.57% change from the last price of $5.63. Highest Price Target $6.00. Average Price Target $6.00.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comAccording to our current ABC stock forecast, the value of AmerisourceBergen shares will rise by 0.00% and reach $ 179.98 per share by November 22, 2023. According to our technical indicators, the current …

5 ago 2023 ... The forecasts range from a low of 15.15 to a high of $39.90. The average price target represents an increase of 347.52% from its latest reported ...ADMA Stock 12 Months Forecast. $6.00. (51.90% Upside) Based on 2 Wall Street analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $6.00 with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 51.90% change from the last price of $3.95.2,065.00 -2.10(-0.10%) AbCellera Biologics Inc. (ABCL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 4.7800 +0.0500 (+1.06%) At close: 04:00PM EST 4.7600 -0.02 (-0.42%)... Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Instagram:https://instagram. what bank do rich people useotcmkts grlfwhich trading platform is best for optionsiovance biotherapeutics stock Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M.Nov 21, 2023 · Future criteria checks 4/6. Palantir Technologies is forecast to grow earnings and revenue by 34.8% and 18% per annum respectively. EPS is expected to grow by 33.7% per annum. Return on equity is forecast to be 18.4% in 3 years. missfreshabb share price "ABCL" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "ABCL" projections. At Walletinvestor.com we … velo3d spacex ABCL. The Nasdaq Stock Market. Indicate by check mark whether the registrant (1) ... The market price of our common stock could decline if one or more of these ...AbCellera Biologics ’s ( ABCL) Moving Averages Convergence Divergence (MACD) indicator is -0.21, suggesting AbCellera Biologics is a Sell. AbCellera Biologics ’s ( ABCL) 20-Day exponential moving average is 4.29, while AbCellera Biologics ’s ( ABCL) share price is $4.43, making it a Sell. AbCellera Biologics ’s ( ABCL) 50-Day ... AbCellera Biologics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ABCL updated stock price target summary.